UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Rhea-AI Summary

UroGen Pharma (Nasdaq: URGN) will report third quarter 2025 financial results on Thursday, November 6, 2025 prior to market open. A live audio webcast and conference call will follow at 10:00 AM Eastern Time. Investors can access the live webcast and a replay on UroGen’s Investor Relations website; the replay will be available for approximately 30 days. The announcement covers the timing and access details for the Q3 2025 earnings release and related investor call.

News Market Reaction

+0.35%

1 alert

+0.35% News Effect

On the day this news was published, URGN gained 0.35%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET

PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6^th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma. 

INVESTOR CONTACT:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083

FAQ

When will UroGen (URGN) report third quarter 2025 results?

UroGen will report Q3 2025 results on Thursday, November 6, 2025 prior to the market open.

What time is the UroGen (URGN) Q3 2025 conference call and webcast?

The live audio webcast and conference call are scheduled for 10:00 AM Eastern Time on November 6, 2025.

How can investors access the UroGen (URGN) earnings webcast on November 6, 2025?

Investors can access the live webcast via UroGen’s Investor Relations website.

Will there be a replay of the UroGen (URGN) Q3 2025 earnings call?

Yes, a replay will be available on the company’s Investor Relations website for approximately 30 days after the live webcast.

Is the UroGen (URGN) Q3 2025 call before or after market open?

The Q3 2025 financial results will be released prior to the market open, with the call at 10:00 AM ET.